This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital malformations of aortic and mitral valves대동맥판 및 승모판의 선천기형 (대동맥판·승모판선천기형)

Contents and key points
ItemDetails
A. Classification codesICD-10: Q23 (Congenital malformations of aortic and mitral valves) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsBicuspid aortic valve (BAV), congenital aortic stenosis/regurgitation, congenital mitral stenosis/regurgitation, parachute mitral valve, mitral valve bileaflet malformation, left heart hypoplasia
C. Adult onsetBicuspid aortic valve is the most common adult-onset Q23 type, most often first presenting with symptoms in adulthood (40s–60s) as it progresses to stenosis or regurgitation.
1. HistoryBicuspid aortic valve described by Vesalius in 1543; congenital mitral stenosis described by Chevers in 1902; BAV–aortic association noted since the 1990s
2. CausesAbnormal semilunar valve commissure formation (BAV); endocardial cushion abnormality (congenital mitral valve malformation); genetic factors such as NOTCH1
3. GeneticsNOTCH1 (BAV, aortic abnormalities), GATA5, ROBO4, ENG variants; association of Turner syndrome (45,X) with BAV
4. General epidemiologyBAV 1–2 per 100 people (most common congenital heart malformation), male predominance 3:1; congenital mitral stenosis rare
5. PathophysiologyBAV: failure of formation of one of the two commissures during conotruncal separation; mitral valve malformation: abnormal endocardial cushion and valve development
6. SymptomsBAV: angina, syncope, and heart failure in adulthood (with progression of aortic stenosis), aortic dissection (complicating aortic dilation); congenital mitral stenosis: pulmonary edema in infancy
7. SignsBAV (stenosis): systolic ejection murmur at the right sternal border, aortic ejection click, narrow pulse pressure; BAV (regurgitation): diastolic decrescendo murmur
8. ScreeningEchocardiography (aortic diameter measurement mandatory when BAV is found), BAV screening in Turner syndrome, screening of first-degree relatives recommended
9. DiagnosisTransthoracic/transesophageal echocardiography, cardiac MRI (aortic morphology and volume), CT angiography (aortic measurement)
10. TreatmentBAV stenosis: TAVI or surgical valve replacement; BAV regurgitation: repair preferred; aortic dilation: apply criteria for prophylactic surgery
11. PrognosisBAV itself is asymptomatic with near-normal life expectancy, but the risk of aortic aneurysm and dissection is 4–9 times higher than in the general population, requiring continued follow-up
12. PreventionFamily screening after BAV diagnosis, blood pressure control, prevention of infective endocarditis, regular aortic imaging follow-up
13. ReferencesBicuspid aortic valve: a 26-year review of the natural history … and 9 other papers

1. History

Among congenital malformations of the aortic and mitral valves, the most frequent and clinically important is bicuspid aortic valve (BAV). The first description of bicuspid aortic valve dates back to Andreas Vesalius in 1543, and Peacock later left a systematic pathological description in 1858. In the early 20th century, Osler reported the clinical observation that bicuspid aortic valves are susceptible to infective endocarditis. Until the 1970s, the long-term natural history of BAV and its association with aortic complications were not sufficiently recognized, but with advances in echocardiography and cardiac MRI in the 1990s–2000s, it was established that patients with BAV have a markedly higher risk of aortic dilation, aortic aneurysm, and dissection than the normal population.

Surgical treatment of congenital aortic stenosis was first performed by Bailey in 1955 via a transventricular approach, and after the introduction of cardiopulmonary bypass, open valvotomy under direct vision became standardized. In 1984, Lababidi et al. applied balloon aortic valvuloplasty to pediatric congenital aortic stenosis, bringing interventional cardiology into this field. Transcatheter aortic valve implantation (TAVI) for adult aortic stenosis developed rapidly after Cribier's first success in 2002 and is now established as a standard treatment for high- and intermediate-risk adult patients.

Surgical approaches to congenital mitral valve malformations developed in the 1950s–60s with the development of mitral valve repair under cardiopulmonary bypass. Carpentier's establishment of mitral valve repair techniques in 1983 was a turning point for valve-preserving surgery, and today the principle of prioritizing valve repair wherever possible is established for congenital mitral stenosis and regurgitation as well. The history of surgical correction of hypoplastic left heart syndrome (HLHS) began with the development of the Norwood procedure in 1983 and has since evolved into various modifications such as the hybrid approach.


2. Causes

Bicuspid aortic valve (BAV) is a malformation in which two of the three semilunar cusps of the aortic valve (left coronary, right coronary, and noncoronary cusps) fuse with each other during development, resulting in a bicuspid form. During embryonic conotruncal septation, abnormal formation of the valve commissures results in one of the three commissures failing to form or two cusps fusing. BAV morphology is divided by fusion pattern into right–left coronary cusp fusion (most common, about 70–80%), right coronary–noncoronary cusp fusion, and left coronary–noncoronary cusp fusion, and each morphology is associated with an aortic phenotype (pattern of ascending aortic dilation).

The causes of congenital mitral valve malformations are diverse. Parachute mitral valve is a malformation in which the mitral chordae tendineae attach to only one papillary muscle, restricting blood flow through the mitral orifice and causing congenital mitral stenosis. Double-orifice mitral valve is a malformation in which a fibrous bridge forms in the middle of the anterior mitral leaflet, creating two mitral orifices. These malformations are caused by abnormal endocardial cushion development and abnormal formation of the valve apparatus, and often occur in combination with atrioventricular septal defect, aortic arch anomalies, and abnormal left heart development.

Hypoplastic left heart syndrome (HLHS) is a complex malformation in which the left ventricle, mitral valve, aortic valve, and ascending aorta are all severely underdeveloped; reactive underdevelopment due to reduced fetal left heart blood flow (congenital mitral atresia, congenital aortic atresia) is proposed as the key mechanism. As environmental factors, rubella infection and lithium exposure during pregnancy have been reported to be associated with some left heart valve malformations.


3. Genetics

The most important genetic factor in bicuspid aortic valve is the NOTCH1 gene (9q34.3). NOTCH1 regulates a signaling pathway essential for heart valve development, and NOTCH1 loss-of-function variants are associated not only with BAV but also with aortic abnormalities (aortic bisegmentation, aortic stenosis). In addition to single-gene variants, variants in GATA5, ROBO4, and ENG (endoglin, associated with hereditary hemorrhagic telangiectasia) have been reported to be related to BAV. Autosomal dominant familial clustering of BAV is observed, and in some families it is accompanied by variants in genes involved in cardiac left–right asymmetric development.

Turner syndrome (45,X) has a very strong association with BAV, with BAV occurring in about 30% of women with Turner syndrome. Besides BAV, coarctation of the aorta and aortic dilation are common cardiovascular phenotypes of Turner syndrome. Therefore, cardiovascular evaluation is essential at the diagnosis of Turner syndrome, and regular aortic imaging follow-up is recommended. In Marfan syndrome (FBN1) and Loeys-Dietz syndrome (TGFBR1/2), aortic valve abnormalities may also accompany aortic lesions, but valve malformations in these syndromes have a different mechanism from BAV.

The genetics of congenital mitral valve malformations are less studied than those of BAV, but some GATA4 and TBX20 variants have been reported. Parachute mitral valve often appears as part of the left heart hypoplasia spectrum (SHONE complex), and the genetic factors in this complex may be shared with aortic stenosis, coarctation of the aorta, and BAV.


4. General epidemiology

Bicuspid aortic valve (BAV) is the most common congenital heart malformation in the general population, with a prevalence of about 1–2% (0.5–2% of the adult population). This is more frequent than ventricular septal defect, but many patients remain asymptomatic for a long time, so diagnosis is often delayed. It is about 2–3 times more frequent in men than in women. The prevalence in Asian countries including Korea may be similar to or somewhat lower than in Western countries, but large-scale cohort data are still limited.

Congenital aortic stenosis (with or without BAV) occurs in about 0.2–0.4 per 1,000 live births and is 4 times more common in boys. Congenital mitral valve malformations (including congenital mitral stenosis) are relatively rare at about 0.2–0.3 per 1,000 live births. Hypoplastic left heart syndrome (HLHS) occurs in about 2–3 per 10,000 live births and is a critical malformation that results in death within days after birth if untreated. In about 25–30% of adult patients with BAV, aortic stenosis or regurgitation progresses over the natural course up to age 60–80 and requires surgery, making it a major cause of aortic valve surgery in the elderly.


5. Pathophysiology

The pathophysiology of BAV begins with abnormal formation of the valve commissures during conotruncal separation. Normally, the three semilunar cusp primordia (cushions) of the aortic valve grow evenly and are separated by commissures. If commissure formation between two cusp primordia fails in this process, those two cusps fuse into a bicuspid form. At the molecular level, NOTCH1 signaling plays an essential role in endocardial-to-mesenchymal transition (EMT) of the valve primordia and commissure formation, and with loss of NOTCH1 function, the valve primordia do not separate normally.

In patients with BAV, aortic wall abnormalities arise not only from physical stress due to abnormal flow but also from the intrinsic structural fragility of the smooth muscle cells and elastic fibers of the aortic media due to NOTCH1 pathway abnormalities. This is called 'flow-independent aortopathy,' and it explains why aortic dilation progresses in BAV patients even without significant aortic stenosis or regurgitation. The key mechanism of congenital mitral stenosis is that abnormal development of the valve apparatus (papillary muscles, chordae tendineae) concentrates blood flow and causes stenosis. In parachute mitral valve, all chordae converge on a single papillary muscle, restricting valve motion.


6. Symptoms

Most patients with BAV remain asymptomatic for decades. Symptoms mainly appear as a result of valve dysfunction—progression of aortic stenosis or development of aortic regurgitation—and the typical age of symptom onset is the 40s–60s. When aortic stenosis progresses to severe, the three cardinal symptoms of angina, exertional syncope, and heart failure appear, and from this point survival drops sharply without treatment. In aortic regurgitation, after a long asymptomatic course, dyspnea, palpitations, nocturnal cough, and orthopnea develop.

As aortic dilation associated with BAV progresses, acute aortic dissection may occur, an emergency accompanied by severe chest pain (tearing, radiating to the back or abdomen). Because aortic dissection can occur suddenly in asymptomatic BAV patients, the importance of periodic aortic imaging follow-up is emphasized. Congenital mitral stenosis presents in infancy or childhood with pulmonary edema (dyspnea during feeding, cyanosis, tachypnea), reduced exercise capacity, and recurrent pneumonia. HLHS is an emergency presenting in the neonatal period with rapid heart failure and cardiogenic shock as the ductus arteriosus closes.


7. Signs

In aortic stenosis due to BAV, a harsh systolic ejection murmur at the upper right sternal border (2nd intercostal space) or transmitted to the carotid arteries is characteristic, and when the valve is pliable, an aortic ejection click preceding the systolic murmur is heard. In advanced stenosis, the aortic component of the second heart sound (A2) diminishes, and a narrow pulse pressure and a slow, delayed upstroke pulse (pulsus parvus et tardus) appear. In aortic regurgitation, a high-pitched decrescendo diastolic murmur beginning in early diastole is heard at the left sternal border, the pulse pressure widens, and a characteristic Corrigan's pulse accompanied by elevated systolic and lowered diastolic blood pressure is observed.

In congenital mitral stenosis, a low-pitched diastolic apical murmur (after the opening snap) is heard, and P2 is accentuated when pulmonary hypertension develops. Neonates with HLHS may not be cyanotic before the ductus arteriosus closes, but with closure they rapidly progress to circulatory failure, metabolic acidosis, and multiple organ failure. Chest X-ray in HLHS shows cardiomegaly, pulmonary congestion, and a narrow mediastinum (narrow aorta), and ECG shows prominent right ventricular hypertrophy.


8. Screening

Screening for BAV is selective in the general population, but systematic screening is recommended in certain high-risk groups. Echocardiographic screening of first-degree relatives (parents, siblings, children) of BAV patients is recommended by AHA/ACC guidelines (class I), allowing early detection of BAV and aortic abnormalities among asymptomatic family members. In patients with Turner syndrome, echocardiography and aortic imaging at diagnosis and regularly thereafter are mandatory screening tests.

In general adults, if a characteristic systolic ejection click or murmur is found on cardiac auscultation, it is promptly confirmed with echocardiography. Prenatal screening for congenital aortic stenosis or mitral valve malformations is based on detailed fetal echocardiography at 18–22 weeks of gestation. The prenatal detection rate of HLHS exceeds 90% at specialized centers, and prenatal diagnosis allows planned delivery and immediate initiation of treatment, greatly improving neonatal outcomes.


9. Diagnosis

Transthoracic echocardiography (TTE) is the primary tool for diagnosing BAV and evaluating valve function. In the short-axis view, the two cusps and the fusion line (raphe) are identified, and valve opening area, pressure gradient, and degree of valve regurgitation are measured. At the same time, the diameter of the ascending aorta must be measured to assess for dilation. When the acoustic window is poor, transesophageal echocardiography (TEE) is used as a supplement. Cardiac MRI (CMR) is the standard for accurately measuring aortic morphology (bicuspid aortopathy pattern) and volume and for quantifying aortic valve regurgitant volume. CT angiography (CTA) evaluates the overall morphology of the ascending aorta, aortic arch, and descending aorta at high resolution and is used for surgical planning. Cardiac catheterization is performed in congenital aortic stenosis for planning before percutaneous balloon valvuloplasty or TAVI.


10. Treatment

Treatment of aortic stenosis in BAV is indicated for severe stenosis (mean pressure gradient ≥40 mmHg or valve area ≤1 cm²) or symptom onset. In children and adolescents, percutaneous balloon aortic valvuloplasty (BAV) is used as first-line palliative treatment for congenital aortic stenosis, but open-heart surgery is needed when BAV dysplasia is severe. In adults, surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI) is the main treatment, and the 2020 ACC/AHA guideline applies TAVI or SAVR after assessing anatomical suitability.

Aortic dilation associated with BAV (ascending aorta ≥5.5 cm, or ≥5.0 cm + risk factors, or rapid growth) is an indication for prophylactic aortic surgery. Surgical indications for aortic valve regurgitation are symptom onset or, even if asymptomatic, reduced left ventricular systolic function (LVEF <60%) or marked left ventricular dilation (LVESD >50 mm). Valve reconstruction (valve-sparing root replacement, David or Yacoub procedure) is preferred whenever possible. Treatment of congenital mitral valve malformations is, in principle, surgical mitral valve repair, with bioprosthetic or mechanical valve replacement performed when repair is not possible. HLHS requires palliative treatment through three-stage surgery (Norwood → Glenn → Fontan) or heart transplantation.


11. Prognosis

With BAV alone, near-normal life expectancy can be expected, but in long-term follow-up aortic complications are the main factor determining prognosis. The risk of aortic dissection in BAV patients is 4–9 times higher than in the population with a normal aortic valve, which is the basis for continued aortic imaging follow-up. When aortic stenosis develops, long-term survival after valve replacement approaches that of the normal population. However, bioprosthetic valves may undergo structural valve deterioration (SVD) after 15–20 years, requiring reoperation. Mechanical valves do not undergo structural deterioration but require lifelong anticoagulation.

Long-term prognosis after surgical correction of congenital mitral stenosis varies with the complexity of the malformation; reoperation is more often needed when multiple left heart malformations are present, as in SHONE complex, than in simple parachute mitral valve. The 10-year survival after completion of the Fontan pathway in HLHS is 70–80%, but because of long-term complications (protein-losing enteropathy, Fontan failure, liver fibrosis, arrhythmia), continued intensive follow-up is needed into adulthood.


12. Prevention

Systematic echocardiographic screening of first-degree relatives at BAV diagnosis is an effective preventive strategy for early detection of asymptomatic BAV and aortic abnormalities within the family. In patients diagnosed with BAV, regular aortic imaging follow-up (echocardiography or MRI, at 1–3-year intervals depending on aortic diameter) is key to determining the timing of prophylactic surgery for aortic aneurysm and dissection. Because hypertension further increases the risk of aortic dissection in BAV patients, blood pressure must be strictly controlled to a target of 130/80 mmHg or lower.

BAV patients have a higher risk of infective endocarditis than patients with a normal aortic valve, so antibiotic prophylaxis before dental or invasive procedures is applied when they meet the criteria for the high-risk endocarditis group. Strenuous competitive sports are restricted when there is moderate or greater aortic stenosis or regurgitation, or aortic dilation (≥4.5 cm). In patients with Turner syndrome, there is evidence that estrogen replacement therapy may partially reduce aorta-related cardiovascular risk. Preconception genetic counseling should, considering the heritability of BAV, include risk assessment for the next generation and planning of prenatal fetal echocardiography.


13. References

  1. Siu SC, Silversides CK. Bicuspid aortic valve disease. Journal of the American College of Cardiology. 2010;55(25):2789–2800. DOI: 10.1016/j.jacc.2009.12.068. PMID: 20579544.

  2. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA. 2011;306(10):1104–1112. DOI: 10.1001/jama.2011.1286. PMID: 21912006.

  3. Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437(7056):270–274. DOI: 10.1038/nature03940. PMID: 16025100.

  4. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. Journal of the American College of Cardiology. 2021;77(4):e25–e197. DOI: 10.1016/j.jacc.2020.11.018. PMID: 33342586.

  5. Tzemos N, Therrien J, Yip J, et al. Outcomes in adults with bicuspid aortic valves. JAMA. 2008;300(11):1317–1325. DOI: 10.1001/jama.300.11.1317. PMID: 18799444.

  6. Fedak PW, Verma S, David TE, et al. Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation. 2002;106(8):900–904. DOI: 10.1161/01.cir.0000027905.26586.e8. PMID: 12186790.

  7. Hinton RB Jr, Martin LJ, Tabangin ME, et al. Hypoplastic left heart syndrome is heritable. Journal of the American College of Cardiology. 2007;50(16):1590–1595. DOI: 10.1016/j.jacc.2007.07.021. PMID: 17936162.

  8. Bondy CA. Aortic coarctation and bicuspid aortic valve in Turner syndrome. Current Opinion in Endocrinology, Diabetes and Obesity. 2015;22(1):50–55. DOI: 10.1097/MED.0000000000000126. PMID: 25405659.

  9. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis. European Heart Journal. 2015;36(44):3075–3128. DOI: 10.1093/eurheartj/ehv319. PMID: 26320109.

  10. Cripe L, Andelfinger G, Martin LJ, et al. Bicuspid aortic valve is heritable. Journal of the American College of Cardiology. 2004;44(1):138–143. DOI: 10.1016/j.jacc.2004.03.050. PMID: 15234424.